In the Original Investigation titled “Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury: A Randomized Clinical Trial,”1 published March 16, 2022, Nastasia James was missing from the list of Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators. This article has been corrected.1
Reference
- 1.Puskarich MA, Ingraham NE, Merck LH, et al. ; Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators . Efficacy of losartan in hospitalized patients with COVID-19–induced lung injury: a randomized clinical trial. JAMA Netw Open. 2022;5(3):e222735. doi: 10.1001/jamanetworkopen.2022.2735 [DOI] [PMC free article] [PubMed] [Google Scholar]